Centre for Molecular Oncology: Recent submissions
Now showing items 141-160 of 272
-
Urine metallomics signature as an indicator of pancreatic cancer.
(Royal Society of Chemistry, 2020-03-25)Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer. Its high mortality rate is attributed largely to the difficulty of early diagnosis. Analysis of urine is an excellent non-invasive approach ... -
Systemic delivery and SPECT/CT in vivo imaging of 125I-labelled oncolytic adenoviral mutants in models of pancreatic cancer.
(2019-09-06)Early phase clinical trials have demonstrated good therapeutic index for oncolytic adenoviruses in patients with solid tumours when administered intratumorally, resulting in local tumour elimination. Entrapment and binding ... -
A multicentre retrospective cohort study of ovarian germ cell tumours: evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
(Elsevier, 2019-04-04)Background Adult guidelines recommend BEP (bleomycin, etoposide, cisplatin) for all ovarian germ cell tumours, causing debilitating toxicities in young patients who will survive long term. Paediatricians successfully ... -
Risk of pancreatic cancer associated with family history of cancer and other medical conditions by accounting for smoking among relatives
(Oxford University Press, 2018-01-10)Background Family history (FH) of pancreatic cancer (PC) has been associated with an increased risk of PC, but little is known regarding the role of inherited/environmental factors or that of FH of other comorbidities in ... -
Copy number signatures and mutational processes in ovarian carcinoma
(Nature Research (part of Springer Nature), 2018-08-13)The genomic complexity of profound copy number aberrations has prevented effective molecular stratification of ovarian cancers. Here, to decode this complexity, we derived copy number signatures from shallow whole-genome ... -
A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk
(Oxford University Press, 2017-04-05)Background Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed in late adulthood; therefore, many patients suffer or have suffered from other diseases. Identifying disease patterns associated with PDAC risk may ... -
Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling.
(FEBS Press and John Wiley & Sons Ltd., 2019-01-28)Perineural invasion (PNI) is a common and characteristic feature of pancreatic ductal adenocarcinoma (PDAC) that is associated with poor prognosis, tumor recurrence, and generation of pain. However, the molecular alterations ... -
The Identification and Interpretation of cis-Regulatory Noncoding Mutations in Cancer
(MDPI, 2018-12-20)In the need to characterise the genomic landscape of cancers and to establish novel biomarkers and therapeutic targets, studies have largely focused on the identification of driver mutations within the protein-coding gene ... -
AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting.
(2019-07-02)Anterior gradient 2 (AGR2), a protein disulfide isomerase, shows two subcellular localizations: intracellular (iAGR2) and extracellular (eAGR2). In healthy cells that express AGR2, the predominant form is iAGR2, which ... -
IW-Scoring: an Integrative Weighted Scoring framework for annotating and prioritising genetic variations in the noncoding genome. Nucleic Acids Research
(Oxford University Press, 2018-01-30)The vast majority of germline and somatic variations occur in the noncoding part of the genome, only a small fraction of which are believed to be functional. From the tens of thousands of noncoding variations detectable ...